Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Thomas Haeder"'
Autor:
Sagar Lonial, Afsaneh Abdolzade-Bavil, Asher Chanan-Khan, Markus Ruehle, Farima Barmaki-Rad, Nikhil C. Munshi, Suraj Chandwani, George Somlo, Kevin R. Kelly, Sundar Jagannath, Ashot Minasyan, Sumit Madan, Andrea Wartenberg-Demand, Eva Herrmann-Keiner, Todd M. Zimmerman, Leonard T. Heffner, Sikander Ailawadhi, Faiza Rharbaoui, Thomas Haeder, David S. Siegel, Kenneth C. Anderson
Publikováno v:
The Lancet Haematology. 8:e794-e807
Summary Background Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138 and synergistically enhances the antitumor activity of lenalidomide in preclinical models of multiple myeloma. This phase 1/2a study was done to deter
Autor:
Sagar Lonial, Sundar Jagannath, Jacalyn Rosenblatt, Asher Chanan-Khan, Nikhil C. Munshi, Todd M. Zimmerman, Sikander Ailawadhi, Faiza Rharbaoui, Andrea Wartenberg-Demand, Thomas Haeder, Kenneth C. Anderson, Markus Ruehle, Leonard T. Heffner
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:372-380
Background Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. Patients and Methods We report from 2 clinical studies of patients with relapsed and/or refractory MM
Autor:
Sagar Lonial, Andrea Wartenberg-Demand, Ann Mohrbacher, Farima Barmaki-Rad, Kenneth C. Anderson, Thomas Haeder, David S. Siegel, Todd M. Zimmerman, Markus Rühle, Kevin R. Kelly, Eva Herrmann, Nikhil C. Munshi, Leonard T. Heffner, Asher Chanan-Khan, Sumit Madan, Sundar Jagannath, George Somlo
Publikováno v:
Blood. 128:4486-4486
Background: BT062 (Biotest AG, Dreieich, Germany) is an antibody-drug conjugate (ADC) comprising a CD138-binding chimerized antibody and the cytotoxic maytansinoid, DM4. It is designed to target and kill CD138-positive cancer cells. CD138 (Syndecan-1
Autor:
Farima Barmaki-Rad, Sagar Lonial, Sikander Ailawadhi, Pankaj M. Patel, Kenneth C. Anderson, Vivek Roy, Asher Chanan-Khan, Andrea Wartenberg-Demand, Kevin R. Kelly, Nikhil C. Munshi, Todd M. Zimmerman, Thomas Haeder, David S. Siegel, Leonard T. Heffner, Anand B. Karnad, Sundar Jagannath, Allen L. Greenberg, Shailesh Chavan, George Somlo
Publikováno v:
Blood. 124:4736-4736
Background: BT062 (Biotest AG Dreieich, Germany) is an antibody-drug conjugate (ADC), comprising the anti-CD138 chimerized MAb (nBT062) and the maytansinoid DM4 as a cytotoxic agent. It is designed to bind to CD138 on cancer cells, and then release D
Autor:
Kevin R. Kelly, Asher Chanan-Khan, George Somlo, Leonard T Heffner, David S Siegel, Todd M Zimmerman, Sundar Jagannath, Nikhil C. Munshi, Sagar Lonial, Vivek Roy, Markus Ruehle, Shailesh Chavan, Pankaj Patel, Markus Rothenburger, Andrea Wartenberg-Demand, Thomas Haeder, Kenneth C. Anderson
Publikováno v:
Blood. 122:758-758
Background BT062 (Biotest AG Dreieich, Germany) is an antibody-drug conjugate, comprising the anti-CD138 chimerized MAb (nBT062) and the maytansinoid DM4 as cytotoxic agent. Once bound to CD138 on a target cell, the conjugate is internalized and rele
Autor:
Jacalyn Rosenblatt, Michelle A. Beelitz, Robert J. Lutz, Thomas Haeder, Frank Osterroth, Kenneth C. Anderson, Niklas Czeloth, Todd M. Zimmerman, Kelvin P. Lee, Sagar Lonial, Leonard T. Heffner, Nikhil C. Munshi, Markus Ruehle, Andrea Wartenberg-Demand, Sundar Jagannath
Publikováno v:
Blood. 120:4042-4042
Abstract 4042 Background: CD138 (Syndecan-1) is highly overexpressed in various solid tumors and hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells. BT062 (Biotest AG
Autor:
David Avigan, Thomas Haeder, Andrea Wartenberg-Demand, Todd M. Zimmerman, Kenneth C. Anderson, Michelle A. Beelitz, Robert J. Lutz, Asher A. Chanan-Khan, Frank Osterroth, Markus Ruehle, Sagar Lonial, Christoph Uherek, André Engling, Gabriele Niemann, Leonard T. Heffner, Sundar Jagannath, Nikhil C. Munshi
Publikováno v:
Blood. 118:305-305
Abstract 305 Background: CD138 (Syndecan-1) is highly overexpressed in various solid tumors and hematological malignancies and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells. BT062 (Biotest AG Dr
Autor:
Leonard T. Heffner, Gabriele Niemann, Asher A. Chanan-Khan, David Avigan, Andrea Wartenberg-Demand, Sundar Jagannath, Markus Ruehle, Nikhil C. Munshi, Kenneth C. Anderson, Robert J. Lutz, Thomas Haeder, Frank Osterroth, Christoph Uherek
Publikováno v:
Blood. 116:3060-3060
Abstract 3060 Background: CD138 represents one of the most reliable target antigens for identification of multiple myeloma (MM) cells and has been reported to be a highly sensitive and specific diagnostic marker of MM. BT062 (Biotest AG Dreieich, Ger
Autor:
Kathleen R. Whiteman, Thomas Haeder, Olga Ab, Teru Hideshima, Chantal Zuber, Benjamin Daelken, Frank Osterroth, Robert J. Lutz, Christoph Uherek, Silke Aigner
Publikováno v:
Blood. 116:3008-3008
Abstract 3008 Background: BT062 represents a CD138 specific antibody-drug conjugate comprising a chimerized anti-CD138 antibody conjugated to maytansinoid (DM4), an inhibitor of tubulin polymerization. CD138 (syndecan-1) which is highly upregulated o
Autor:
David Avigan, Sundar Jagannath, Andrea Wartenberg-Demand, Kenneth C. Anderson, Asher A. Chanan-Khan, Robert J. Lutz, Leonard T. Heffner, Markus Ruehle, Nikhil C. Munshi, Thomas Haeder, Christoph Uherek, Kelvin P. Lee
Publikováno v:
Blood. 114:1862-1862
Abstract 1862 Poster Board I-887 Background: Biotest AG (Dreieich, Germany) is developing the immunoconjugate BT062, which comprises the anti-CD138 chimerized MAb (nBT062) and the cytotoxic agent maytansinoid (DM4). Once bound to CD138 on a target ce